ArticleEuropean journal of nuclear medicine and molecular imaging2020
Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Short-term memory conjunctive binding in subjective cognitive decline: A PET biomarker-based study.Journal of neurology · 2026Article
- Cognitive training effects in mild cognitive impairment with and without amyloid pathology.Dementia & neuropsychologia · 2026Article
- A radiomics model predicts progression from mild cognitive impairment to alzheimer's disease using structural MRI.Scientific reports · 2025Article
- Neuroinflammation and amyloid load in different age groups of individuals with Down syndrome: A PET imaging study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Diagnosing preclinical and clinical Alzheimer's disease with visual atrophy scales in the clinical practice.Arquivos de neuro-psiquiatria · 2025Article
- Stable brain PET metabolic networks using a multiple sampling scheme.Network neuroscience (Cambridge, Mass.) · 2025Article
- Lower GLUT1 and unchanged MCT1 in Alzheimer's disease cerebrovasculature.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome.Movement disorders clinical practice · 2024Article
- Analysis of positron emission tomography hypometabolic patterns and neuropsychiatric symptoms in patients with dementia syndromes.CNS neuroscience & therapeutics · 2023Article
- Biomarkers for dementia in Latin American countries: Gaps and opportunities.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice.Journal of Alzheimer's disease reports · 2023Review
- The Discourse Profile in Corticobasal Syndrome: A Comprehensive Clinical and Biomarker Approach.Brain sciences · 2022Article
- Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2022Article
- The Association Between Acquired Color Deficiency and PET Imaging of Neurodegeneration in Mild Cognitive Impairment and Alzheimer Disease.Investigative ophthalmology & visual science · 2022Article
- Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology.Journal of Alzheimer's disease : JAD · 2022Article
- Role of tau deposition in early cognitive decline in Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- In the era of FDG PET, is it time for brain perfusion SPECT to gain a place in Alzheimer's disease imaging biomarkers?European journal of nuclear medicine and molecular imaging · 2021Article
- Clinical Impact of PET WithFrontiers in neurology · 2021Article
- A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2021Article
- Metabolic and Structural Signatures of Speech and Language Impairment in Corticobasal Syndrome: A Multimodal PET/MRI Study.Frontiers in neurology · 2021Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
purpose[
methodsElderly individuals (N = 108) clinically classified as controls (N = 27), aMCI (N = 43) or mild probable AD (N = 38) were included. Authors assessed their A(N) profiles and classified [
resultsAD presented with higher rates of A+ and (N)+. There was also a higher proportion of A+ and (N)+ individuals in the aMCI group in comparison to controls, however without statistical significance regarding the A staging. There was a significant association between amyloid positivity and AD (N)+ hypometabolic patterns typical of AD. Non-AD (N)+ hypometabolism was seen in all A- (N)+ cases in the mild probable AD and control groups and [
conclusionThe PET-based staging system unveiled significant A(N) differences between AD and the other groups, whereas aMCI and controls had different (N) staging, explaining the cognitive impairment in aMCI. [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.